Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such, and methods of use thereof are each provided.
1. A method of vaccinating a subject against an HSV-1 infection, the method comprising administering to the subject a recombinant herpes simplex virus-2 (HSV-2) in an amount effective to vaccinate a subject for an HSV-1 infection, wherein the recombinant HSV-2 has a deletion of the HSV-2 glycoprotein D-encoding gene in the genome thereof and comprises a herpes simplex virus-1 (HSV-1) glycoprotein D on a lipid bilayer thereof.
2. The method of claim 1 , wherein the surface glycoprotein is present on a lipid bilayer thereof by way of infecting a cell with a recombinant HSV-2 having a deletion of an HSV-2 glycoprotein D-encoding gene, wherein the cell is or has been transfected to express the surface glycoprotein on a cell membrane thereof, and wherein the recombinant HSV-2 comprising the surface glycoprotein present on a lipid bilayer is produced from the cell.
3. The method of claim 1 , wherein the subject is administered a subcutaneous priming dose and is administered a second dose subcutaneously or intravaginally.
4. A method of vaccinating a subject against an HSV-2 infection, the method comprising administering to the subject a recombinant herpes simplex virus-2 (HSV-2) in an amount effective to vaccinate a subject for an HSV-1 infection,
wherein the recombinant HSV-2 has a deletion of the HSV-2 glycoprotein D-encoding gene in the genome thereof and comprises a herpes simplex virus-1 (HSV-1) glycoprotein D on a lipid bilayer thereof.
5. The method of claim 4 , wherein the surface glycoprotein is present on a lipid bilayer thereof by way of infecting a cell with a recombinant HSV-2 having a deletion of an HSV-2 glycoprotein D-encoding gene, wherein the cell is or has been transfected to express the surface glycoprotein on a cell membrane thereof, and wherein the recombinant HSV-2 comprising the surface glycoprotein present on a lipid bilayer is produced from the cell.
6. The method of claim 4 , wherein the subject is administered a subcutaneous priming dose and is administered a second dose subcutaneously or intravaginally.
7. A method of vaccinating a subject against an HSV-1 and HSV-2 co-infection, the method comprising administering to the subject a recombinant herpes simplex virus-2 (HSV-2) in an amount effective to vaccinate a subject for an HSV-1 and HSV-2 co-infection,
wherein the recombinant HSV-2 has a deletion of the HSV-2 glycoprotein D-encoding gene in the genome thereof and comprises a herpes simplex virus-1 (HSV-1) glycoprotein D on a lipid bilayer thereof.
8. The method of claim 7 , wherein the surface glycoprotein is present on a lipid bilayer thereof by way of infecting a cell with a recombinant HSV-2 having a deletion of an HSV-2 glycoprotein D-encoding gene, wherein the cell is or has been transfected to express the surface glycoprotein on a cell membrane thereof, and wherein the recombinant HSV-2 comprising the surface glycoprotein present on a lipid bilayer is produced from the cell.
9. The method of claim 7 , wherein the subject is administered a subcutaneous priming dose and is administered a second dose subcutaneously or intravaginally.